Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia

L. Letendre, P. Noel, A. Tefferi, L. A. Solberg, D. A. Gastineau, H. C. Hoagland

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Etoposide (125 mg/m2/d) and carboplatin (200 mg/m2/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.

Original languageEnglish (US)
Pages (from-to)382-384
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
StatePublished - 1995


  • Enterocolitis
  • Etoposide/carboplatin
  • Leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia'. Together they form a unique fingerprint.

Cite this